SCHEMBL2776740

SCHEMBL2776740

Nc1ccc2c(c1)S(=O)(=O)N=CN2C1CCC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCC8 Q09428 1/20 0.34
KCNJ11 Q14654 1/20 0.34
GFER P55789 3/20 0.32
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
MAPT P10636 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
PRKACA P17612 1/20 0.30
GSK3B P49841 1/20 0.30
ROCK1 Q13464 1/20 0.30
MEN1 O00255 1/20 0.30
THRB P10828 1/20 0.30
ALOX15 P16050 1/20 0.30
YWHAG P61981 1/20 0.30
KMT2A Q03164 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2777425 0.83 GRIA2 (0.43) ABCC8KCNJ11ALDH1A1CA12CA2
SCHEMBL2776716 0.81 GRIA2 (0.43) ABCC8KCNJ11ALDH1A1CA12CA2
SCHEMBL2776248 0.80 GRIA2 (0.42) ALDH1A1CA12CA2CA9MEN1
SCHEMBL2777145 0.79 KDM4E (0.41) ABCC8KCNJ11KDM4EALDH1A1MAPT
SCHEMBL2777802 0.77 GRIA2 (0.42) CA1CA2MEN1KMT2A
SCHEMBL2777706 0.77 GRIA1 (0.31) CA1CA2
SCHEMBL2774129 0.77 CCNT1 (0.30)
SCHEMBL2777124 0.75 GRIA1 (0.37) ABCC8KCNJ11CA12CA1CA2
SCHEMBL2776571 0.74 CCNT1 (0.33)
SCHEMBL2775031 0.74 CCNT1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2147915-B1 New cycloalkylated benzothiadiazine derivatives, method of preparing same and pharmaceutical compositions containing them SERVIER LAB (FR) 2010-09-15 EP disclosed
US-7741320-B2 Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2010-06-22 US disclosed
EP-2147915-A1 New cycloalkylated benzothiadiazine derivatives, method of preparing same and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2010-01-27 EP disclosed
US-20100009974-A1 Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them LES LABORATOIRES SERVIER (FR) 2010-01-14 US disclosed
WO-2010004139-A1 NEW CYCLOALKYLATED BENZOTHIADIAZINE DERIVATIVES, METHOD FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009974-A1 Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them ACLY, HCAR1, GABRG1 ABCC8 391/4885KCNJ11 339/4885GFER 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.